WhaleCreep

RA Capital Management, L.P. 13F holdings, Q2 2025

Hedge fundSEC filingsCompare with another fundHoldings as of 2025-06-30, filed 2025-08-14

RA Capital Management, L.P. disclosed 63 US equity positions worth $5.9bn in its Q2 2025 13F filing. Its largest position is ASND at 29.9% of the reported book, followed by PCVX and RYTM. Versus Q1 2025 it opened 6 new positions, added to 9, reduced 9 and exited 28.

$5.9bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
63
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
29.9%
Largest position
The largest single position as a share of the reported equity book.
66.2%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
9
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
73
Quarters on file since Q4 2007
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2025: 6 new, 9 added, 9 reduced, 28 exited

50 of 63
ASND ASCENDIS PHARMA A/SHealthcare29.9%$1.8bn10.28m0.0%held
PCVX VAXCYTE INCHealthcare6.6%$389m11.97m−1.8%reduced
RYTM RHYTHM PHARMACEUTICALS INCHealthcare5.9%$351m5.56m−8.6%reduced
JANX JANUX THERAPEUTICS INCHealthcare4.4%$258m11.19m0.0%held
RNAGBP AVIDITY BIOSCIENCES INC–3.5%$206m7.27m+15%added
ACLXGBX ARCELLX INC–3.4%$200m3.04m0.0%held
ETNBGBP 89BIO INC–3.3%$195m19.89m0.0%held
SPRY ARS PHARMACEUTICALS INCHealthcare3.2%$190m10.86m0.0%held
NEWAMSTERDAM PHARMA COMPANY no ticker–3.1%$184m10.14m0.0%held
SION SIONNA THERAPEUTICS INCHealthcare3.1%$181m10.45m0.0%held
CDTX CIDARA THERAPEUTICS INC–2.8%$164m3.37m+208%added
EWTX EDGEWISE THERAPEUTICS INCHealthcare2.2%$130m9.90m+11%added
LENZ LENZ THERAPEUTICS INCHealthcare2.1%$122m4.18m0.0%held
WVE WAVE LIFE SCIENCES LTDHealthcare2.0%$118m18.20m0.0%held
TYRA TYRA BIOSCIENCES INCHealthcare2.0%$117m12.20m+15%added
GHRS GH RESEARCH PLCHealthcare1.6%$93.6m7.68m+11%added
DYN DYNE THERAPEUTICS INCHealthcare1.6%$92.5m9.71m0.0%held
GERN GERON CORPHealthcare1.4%$85.1m60.38m0.0%held
IRON DISC MEDICINE INCHealthcare1.4%$83.5m1.58m0.0%held
MLYS MINERALYS THERAPEUTICS INCHealthcare1.4%$83.2m6.15m0.0%held
SEPN SEPTERNA INCHealthcare1.2%$73.9m7.00m0.0%held
FULC FULCRUM THERAPEUTICS INCHealthcare1.2%$70.4m10.23m0.0%held
BCAX BICARA THERAPEUTICS INCHealthcare1.1%$64.6m6.96m0.0%held
VOR VOR BIOPHARMA INCHealthcare1.1%$64.2m39.65m0.0%held
TSHA TAYSHA GENE THERAPIES INCHealthcare0.9%$54.4m23.56m+117%added
DNTH DIANTHUS THERAPEUTICS INCHealthcare0.9%$53.4m2.87m0.0%held
RXST RXSIGHT INCHealthcare0.8%$48.1m3.70m−1.1%reduced
TRML TOURMALINE BIO INC–0.7%$40.6m2.54m0.0%held
SRRK SCHOLAR ROCK HLDG CORPHealthcare0.7%$40.3m1.14m0.0%held
CLYM CLIMB BIO INCHealthcare0.7%$39.0m31.42m0.0%held
GPCR STRUCTURE THERAPEUTICS INCHealthcare0.5%$31.5m1.52m0.0%held
SLDB SOLID BIOSCIENCES INCHealthcare0.5%$28.3m5.81m+34%added
METSERA INC no ticker–0.3%$19.2m675,5250.0%held
MNPR MONOPAR THERAPEUTICS INCHealthcare0.3%$18.3m511,2070.0%held
NKTX NKARTA INCHealthcare0.3%$17.9m10.81m0.0%held
LRMR LARIMAR THERAPEUTICS INCHealthcare0.3%$17.5m6.05m0.0%held
ABOS ACUMEN PHARMACEUTICALS INCHealthcare0.3%$17.3m14.93m0.0%held
ELVN ENLIVEN THERAPEUTICS INCHealthcare0.3%$17.0m848,9860.0%held
TVTX TRAVERE THERAPEUTICS INCHealthcare0.3%$17.0m1.15m0.0%held
FDMT 4D MOLECULAR THERAPEUTICS INHealthcare0.3%$16.9m4.56m0.0%held
HNGE HINGE HEALTH INCHealthcare0.3%$15.5m300,000–new
ARTV ARTIVA BIOTHERAPEUTICS INCHealthcare0.3%$14.9m9.85m0.0%held
PEPG PEPGEN INCHealthcare0.2%$11.9m10.69m0.0%held
JBIO JADE BIOSCIENCES INCHealthcare0.2%$10.6m1.06m–new
TNGX TANGO THERAPEUTICS INCHealthcare0.2%$10.2m2.00m–new
ACRV ACRIVON THERAPEUTICS INCHealthcare0.2%$9.9m8.34m0.0%held
ELDN ELEDON PHARMACEUTICALS INC–0.2%$9.7m3.57m0.0%held
RCUS ARCUS BIOSCIENCES INCHealthcare0.2%$9.3m1.14m0.0%held
PERCEPTIVE CAP SOLUTIONS COR no ticker–0.1%$8.0m750,0000.0%held
OMDA OMADA HEALTH INCHealthcare0.1%$7.3m400,000–new

Exited since Q1 2025

28 rows
APGE APOGEE THERAPEUTICS INC1.0%$58.6m
ZLAB ZAI LAB LTD0.8%$46.8m
DAWNGBX DAY ONE BIOPHARMACEUTICALS I0.8%$45.6m
URGN UROGEN PHARMA LTD0.6%$35.5m
CATBUSD ASTRIA THERAPEUTICS INC0.5%$27.3m
KURA KURA ONCOLOGY INC0.4%$26.4m
AEROVATE THERAPEUTICS INC no ticker0.4%$23.1m
IDYA IDEAYA BIOSCIENCES INC0.4%$22.1m
2662247D ITEOS THERAPEUTICS INC0.4%$21.8m
GKOS GLAUKOS CORP0.3%$18.7m
EYPT EYEPOINT INC0.3%$17.2m
CBLL CERIBELL INC0.3%$15.8m
NRIX NURIX THERAPEUTICS INC0.3%$15.8m
INSM INSMED INC0.3%$15.3m
ALEC ALECTOR INC0.2%$11.9m
SERA SERA PROGNOSTICS INC0.2%$11.2m
BCYC BICYCLE THERAPEUTICS PLC0.2%$9.3m
IMTX IMMATICS N.V0.1%$7.9m
DRUG BRIGHT MINDS BIOSCIENCES INC0.1%$7.4m
ACRS ACLARIS THERAPEUTICS INC0.1%$7.1m
XNCR XENCOR INC0.1%$6.1m
HUMA HUMACYTE INC0.09%$5.6m
ZURA ZURA BIO LTD0.07%$4.2m
BIOA BIOAGE LABS INC0.07%$4.0m
BOLD BOUNDLESS BIO INC0.05%$3.3m
STRO SUTRO BIOPHARMA INC0.05%$2.9m
LXEO LEXEO THERAPEUTICS INC0.03%$1.9m
SCLXUSD SCILEX HOLDING CO0.0%$258k

Sector mix

  • Healthcare82.5%
  • Unclassified17.5%

Book over time

Every quarter on file (73)
QuarterPositionsEquity book
Q2 202684$11.5bn
Q1 202685$9.4bn
Q4 202571$9.8bn
Q3 202567$8.1bn
Q2 202563$5.9bn
Q1 202585$6.0bn
Q4 202489$7.5bn
Q3 202481$8.7bn
Q2 202478$7.6bn
Q1 202476$7.9bn
Q4 202362$6.4bn
Q3 202366$5.1bn
Q2 202354$5.3bn
Q1 202359$4.4bn
Q4 202270$4.9bn
Q3 202281$4.7bn
Q2 202288$3.8bn
Q1 202296$4.6bn
Q4 202197$5.7bn
Q3 202195$7.2bn
Q2 202192$6.2bn
Q1 202182$6.6bn
Q4 202082$7.2bn
Q3 202070$5.5bn
Q2 202057$5.1bn
Q1 202048$3.2bn
Q4 201934$3.3bn
Q3 201932$1.7bn
Q2 201925$1.9bn
Q1 201929$2.3bn
Q4 201825$1.7bn
Q3 201826$1.9bn
Q2 201827$1.5bn
Q1 201831$1.3bn
Q4 201727$1.2bn
Q3 201727$1.1bn
Q2 201722$871m
Q1 201724$815m
Q4 201627$706m
Q3 201630$969m
Q2 201632$722m
Q1 201642$782m
Q4 201537$1.0bn
Q3 201547$696m
Q2 201558$928m
Q1 201556$913m
Q4 201448$777m
Q3 201443$622m
Q2 201424$756m
Q1 201429$973m
Q4 201324$648m
Q3 201331$724m
Q2 201325$616m
Q1 201317$407m
Q4 201219$225m
Q3 201221$198m
Q2 201226$223m
Q1 201223$185m
Q4 201118$124m
Q3 201120$90.3m
Q2 201120$108m
Q1 201121$130m
Q4 201016$101m
Q3 201018$101m
Q1 201021$102m
Q4 200914$75.1m
Q2 200916$107m
Q1 200912$184m
Q4 20088$224m
Q3 200820$329m
Q2 200822$220m
Q1 200817$135m
Q4 200723$159m

Where RA Capital Management, L.P. was early

110 rows
VRTX VERTEX PHARMACEUTICALS INCQ1 20082 of 16012.5%12.5%7Exited by Q4 2014+370%
AMAG AMAG PHARMACEUTICALS INCQ2 20081 of 693.4%9.2%7Exited by Q3 2010+2.4%
GILD GILEAD SCIENCES INCQ4 20087 of 1810.7%15.8%6Exited by Q2 2020+192%
BSTC BIOSPECIFICS TECHNOLOGIES COQ1 20091 of 299.0%32.9%7Exited by Q3 2011–
ALXN ALEXION PHARMACEUTICALS INCQ2 20092 of 1476.6%9.6%5Exited by Q2 2011–
UTHR UNITED THERAPEUTICS CORP DELQ2 20092 of 1617.0%7.0%5Exited by Q2 2011+61%
ENZB ENZO BIOCHEM INCQ1 20101 of 400.6%3.9%7Exited by Q1 2014–
ACAD ACADIA PHARMACEUTICALS INCQ1 20111 of 1456.5%21.1%17Exited by Q3 2015+2485%
NVAX NOVAVAX INCQ4 20111 of 1171.0%14.4%24Exited by Q2 2022+192%
SGMOQ SANGAMO THERAPEUTICS INCQ4 20111 of 852.0%13.6%22Exited by Q4 2017+428%
BCRX BIOCRYST PHARMACEUTICALS INCQ1 20121 of 1218.0%11.1%28Held at last filing, Q2 2026+107%
VSTM VERASTEM INCQ1 20121 of 1003.6%3.6%6Exited by Q4 2020−89%
IMMU IMMUNOMEDICS INCQ1 201311 of 1110.6%4.8%6Exited by Q1 2019+492%
ENTA ENANTA PHARMACEUTICALS INCQ2 20131 of 921.3%8.8%8Exited by Q1 2025−68%
INSM INSMED INCQ2 20131 of 1804.7%6.4%9Exited by Q2 2025+538%
OMER OMEROS CORPQ2 20131 of 662.4%2.4%4Exited by Q3 2015+257%
PRTA PROTHENA CORP PLCQ2 20131 of 1011.0%6.7%4Exited by Q2 2014+197%
TXMD THERAPEUTICSMD INCQ2 20131 of 655.5%9.4%13Exited by Q3 2021−61%
PTCT PTC THERAPEUTICS INCQ3 20131 of 1270.9%2.6%7Exited by Q3 2015+124%
TGTX TG THERAPEUTICS INCQ3 20131 of 1140.4%6.8%30Exited by Q1 2022+277%
T8S TESARO INCQ4 20131 of 833.1%3.1%4Exited by Q3 2015+108%
XNCR XENCOR INCQ4 20131 of 1023.8%3.8%13Held at last filing, Q2 2026+76%
MGNX MACROGENICS INCQ4 201310 of 1040.8%2.6%16Held at last filing, Q2 2026−83%
SCYX SCYNEXIS INCQ2 20141 of 470.9%1.1%4Exited by Q2 2015+3.5%
AKBA AKEBIA THERAPEUTICS INCQ2 20142 of 1032.2%2.2%5Exited by Q3 2017−48%
TENX TENAX THERAPEUTICS INCQ3 20143 of 561.5%1.5%10Exited by Q1 2017−50%
CHRS COHERUS BIOSCIENCES INCQ4 20141 of 1053.3%5.2%6Exited by Q2 2016+30%
AUPH AURINIA PHARMACEUTICALS INCQ4 20142 of 1001.2%1.2%3Exited by Q3 2015−17%
ASND ASCENDIS PHARMA A/SQ1 20151 of 1371.9%29.9%46Held at last filing, Q2 2026+1437%
DVAX DYNAVAX TECHNOLOGIES CORPQ1 20151 of 1166.4%6.4%4Exited by Q1 2020−75%
2655787D BLUEPRINT MEDICINES CORPQ2 20151 of 1472.5%2.7%4Exited by Q2 2016−32%
COLL COLLEGIUM PHARMACEUTICAL INCQ2 20151 of 963.0%4.9%4Exited by Q2 2016+1.7%
MCRB SERES THERAPEUTICS INCQ2 20151 of 751.1%2.5%5Exited by Q3 2021−43%
ARDX ARDELYX INCQ2 20152 of 1143.0%4.4%15Exited by Q3 2021−53%
AIMT AIMMUNE THERAPEUTICS INCQ3 20151 of 742.9%2.9%6Exited by Q1 2017−19%
NTRA NATERA INCQ3 20151 of 1671.2%1.3%6Exited by Q3 2022+227%
ACRS ACLARIS THERAPEUTICS INCQ4 20151 of 1146.8%6.8%15Held at last filing, Q2 2026−80%
WVE WAVE LIFE SCIENCES LTDQ4 20151 of 12311.2%26.3%43Held at last filing, Q2 2026−64%
ONC BEIGENE LTDQ1 20164 of 1040.6%1.1%5Exited by Q2 2017+25%
NKTR NEKTAR THERAPEUTICSQ1 20165 of 1455.6%6.5%4Exited by Q4 2023−96%
PTGX PROTAGONIST THERAPEUTICS INCQ3 20162 of 1361.6%2.1%3Exited by Q2 2017−39%
4XC1 KALVISTA PHARMACEUTICALS INCQ4 20161 of 910.6%1.8%15Exited by Q2 2022+108%
KDMN KADMON HLDGS INCQ3 20173 of 762.0%2.0%2Exited by Q1 2018+8.1%
SCPH SCPHARMACEUTICALS INCQ4 20171 of 642.9%2.9%19Exited by Q1 2023−41%
SPRO SPERO THERAPEUTICS INCQ4 20171 of 441.2%1.2%3Exited by Q3 2018+25%
IFRX INFLARX NVQ4 20172 of 575.0%5.0%8Exited by Q4 2025−94%
SG7 SAGE THERAPEUTICS INCQ4 201714 of 1326.3%6.3%5Exited by Q2 2019−3.4%
SLDB SOLID BIOSCIENCES INCQ1 20181 of 951.5%6.8%34Held at last filing, Q2 2026−91%
IOVA IOVANCE BIOTHERAPEUTICS INCQ1 20186 of 1300.9%1.4%5Exited by Q2 2019−44%
RYTM RHYTHM PHARMACEUTICALS INCQ2 20183 of 1143.1%7.3%33Held at last filing, Q2 2026+255%

Concentration and tenure

18.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
70.5%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters